David Wraith
Gründer bei Apitope International NV
Profil
David Wraith is the founder of Apitope International NV (founded in 2002) and currently holds the title of Chief Scientific Officer.
Dr. Wraith is also the founder of Apitope Technology (Bristol) Ltd.
Dr. Wraith's former job positions include being a Member of the Infections & Immunity Board at The Medical Research Council, Head of Pathology & Microbiology at the University of Bristol (1996-2004), and a Member at NIH Research, Inc.
Aktive Positionen von David Wraith
Unternehmen | Position | Beginn |
---|---|---|
Apitope International NV
Apitope International NV BiotechnologyHealth Technology Apitope International NV develops therapeutic vaccines. It operates as a bio-pharmaceutical company that engages in developing peptide therapies. The firm specializes on the discovery and development of revolutionary disease modifying therapies for treating autoimmune and allergic diseases, including multiple sclerosis, and Graves’ disease, FVIII intolerance and uveitis. The company was founded by David Wraith in 2002 and is headquartered in Diepenbeek, Belgium. | Gründer | 07.12.2009 |
Apitope Technology (Bristol) Ltd.
Apitope Technology (Bristol) Ltd. Miscellaneous Commercial ServicesCommercial Services Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies. | Gründer | 01.06.2010 |
Ehemalige bekannte Positionen von David Wraith
Unternehmen | Position | Ende |
---|---|---|
University of Bristol | Corporate Officer/Principal | 01.01.2004 |
The Medical Research Council
The Medical Research Council Miscellaneous Commercial ServicesCommercial Services The Medical Research Council provides human healthcare and social services. It offers funding for biomedical spectrum, fundamental lab-based science, clinical trials and all major disease areas. The company was founded in 1913 and is headquartered in Swindon, the United Kingdom. | Corporate Officer/Principal | - |
NIH Research, Inc.
NIH Research, Inc. Miscellaneous Commercial ServicesCommercial Services NIH Research, Inc. provided healthcare consulting services. The company was headquartered in Coral Springs, FL. | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
Apitope International NV
Apitope International NV BiotechnologyHealth Technology Apitope International NV develops therapeutic vaccines. It operates as a bio-pharmaceutical company that engages in developing peptide therapies. The firm specializes on the discovery and development of revolutionary disease modifying therapies for treating autoimmune and allergic diseases, including multiple sclerosis, and Graves’ disease, FVIII intolerance and uveitis. The company was founded by David Wraith in 2002 and is headquartered in Diepenbeek, Belgium. | Health Technology |
NIH Research, Inc.
NIH Research, Inc. Miscellaneous Commercial ServicesCommercial Services NIH Research, Inc. provided healthcare consulting services. The company was headquartered in Coral Springs, FL. | Commercial Services |
Apitope Technology (Bristol) Ltd.
Apitope Technology (Bristol) Ltd. Miscellaneous Commercial ServicesCommercial Services Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies. | Commercial Services |
The Medical Research Council
The Medical Research Council Miscellaneous Commercial ServicesCommercial Services The Medical Research Council provides human healthcare and social services. It offers funding for biomedical spectrum, fundamental lab-based science, clinical trials and all major disease areas. The company was founded in 1913 and is headquartered in Swindon, the United Kingdom. | Commercial Services |